MEDI Medimmune (MM)

GAITHERSBURG, Md., Dec. 1 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that the Washington Business Journal has named Linda J. Peters, MedImmune's senior vice president, regulatory affairs, as one of the region's leading business women. Ms. Peters was recognized at the 2006 "Women Who Mean Business" awards reception held Thursday, November 30 in Washington, D.C. The "Women Who Mean Business" award honors 25 influential women for significant contributions to their local communities and to the Greater Washington business area. In its third year, the program recognizes women across all industries and professions. "Linda's professional accomplishments, dedication to her work and commitment to corporate community involvement establish her as an exemplary leader for other women in her field," said David M. Mott, MedImmune president and chief executive officer. "She has built a strong, diverse regulatory affairs team at MedImmune, fostering mentorship and expanding the regulatory group's role as a collaborative partner for other functions within the organization." Since Ms. Peters joined MedImmune in February 2005, the biotechnology company's regulatory affairs organization has nearly doubled in size, and the number of regulatory-related filings to the U.S. Food and Drug Administration (FDA) and other regulatory agencies has already exceeded 1,000 this year. Her successful development and expansion of the regulatory function has helped to advance MedImmune's strategic priorities and to establish scalable processes in a time of rapid growth for the company. Recent company milestones resulting in part from Peters' leadership include filing supplemental biologics license applications (sBLAs) for approval of the MedImmune's next- generation intranasal influenza vaccine, filing several Investigational New Drug (IND) applications, and breaking ground on a new cell culture manufacturing facility in Frederick, MD. "Achievement of these critical milestones requires a tremendous amount of regulatory support, and Linda and her team have not only met those needs with great success, but have gone even further to develop and implement processes to help MedImmune continue its extraordinary pattern of growth and success," said Lota S. Zoth, MedImmune's senior vice president and chief financial officer, and a recipient of this leadership award in 2004. In addition to her professional accomplishments, Ms. Peters' recognition as a "Woman Who Means Business" reflects her mentorship of other women in her field and her involvement in volunteer and community-focused activities. She advocates strong corporate community involvement and leads by example; she also actively supports several organizations dedicated to cancer-related research and assisting families of children with cancer. Ms. Peters earned a bachelor's and a master's degree in animal science from Southern Illinois University. She obtained a master's degree in business administration from the J.L. Kellogg School of Management at Northwestern University. Prior to joining MedImmune, Ms. Peters was vice president of global regulatory affairs for the Bioscience and Renal Divisions of Baxter Healthcare. She also held positions of increasing responsibility and Takeda Pharmaceuticals and TAP Pharmaceuticals. Additional Local Recognition for MedImmune, Inc. Separately, MedImmune was recently awarded the 2006 Economic Development and Advancement Award from the Montgomery County Department of Economic Development, which is presented to individuals or employers in Montgomery County who consistently make economic development and workforce development a priority. The company's legal department was also recently named a finalist in the "Outstanding Law Department of the Year" category at the 2006 Washington Metropolitan Area Corporate Counsel Association (WMACCA) Corporate Counsel Awards. In addition, the Maryland Partnership for Prevention recently presented the "2006 Immunization Partnership Award" to Mary Ellen Enos, MedImmune legislation analyst, for outstanding efforts to help prevent and reduce vaccine-preventable diseases in Maryland. MedImmune, in partnership with the Maryland Governor's office and the Centers for Disease Control & Prevention, provided free doses of influenza vaccine for Maryland's elementary school-aged children this year. The award was presented at the 2006 Maryland Immunization Excellence Awards Luncheon in Columbia, Maryland. About MedImmune, Inc. MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com/. This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. DATASOURCE: MedImmune, Inc. CONTACT: Media: Kate Barrett, +1-301-398-4320, or Investors: Beatrice Pierre, +1-301-398-4905, both of MedImmune, Inc. Web site: http://www.medimmune.com/

Copyright